Clinical trials: XLA
Nasolabial Folds
Hyaluronic Acid Filler IMD1 Basic for Correction of Nasolabial Folds
Volunteers receive one injection IMD1 basic of correction of nasolabial folds and are followed-up for up to 36 weeks.
- Trial name
- NCT00429520
- Testing
- Hyaluronic acid filler/IMD1 basic
- Where
- Germany
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Merz Pharmaceuticals GmbH
Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel BTK inhibitor, Orelabrutinib (ICP-022) in Patients with B-cell malignancies.
- Trial name
- NCT04014205
- Testing
- Orelabrutinib (ICP-022)
- Where
- 36 sites in United States, Israel and 2 more
- Volunteers
- 81 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Part1: Advanced B-cell Malignancies, Part2: r/rCLL and r/rMCL
A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies
This is a multicenter, open-label Phase 1 study of acalabrutinib, a selective and irreversible Bruton's tyrosine kinase inhibitor, in Japanese adult patients with advanced B-cell malignancies.
- Conditions
- Part1: Advanced B-cell Malignancies, Part2: r/rCLL and r/rMCL, Part3: Untreated CLL
- Trial name
- NCT03198650
- Testing
- Acalabrutinib, Obinutuzumab
- Where
- 13 sites in Japan
- Volunteers
- 35 people
- Sponsor
- AstraZeneca
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies.
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT03088878
- Testing
- Cirmtuzumab (2-16 kg/mg) plus Ibrutinib, Cirmtuzumab (300mg) plus Ibrutinib, Cirmtuzumab (600 mg) plus ibrutinib
- Where
- 12 sites in United States
- Volunteers
- 95 people
- Sponsor
- Oncternal Therapeutics, Inc
Relapsing-remitting Multiple Sclerosis
A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis
The aim of this protocol is to find out about the safety and effectiveness of M2951 in participants with relapsing multiple sclerosis.
- Trial name
- NCT02975349
- Testing
- Evobrutinib, Tecfidera
- Where
- 56 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 267 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Mantle Cell Lymphoma (MCL)
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).
- Trial name
- NCT02213926
- Testing
- ACP-196 (acalabrutinib)
- Where
- 58 sites in United States, Australia and 8 more
- Volunteers
- 124 people
- Sponsor
- Acerta Pharma BV
Metastatic Pancreatic Adenocarcinoma
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
This is a phase 3 study to evaluate the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma.
- Trial name
- NCT02436668
- Testing
- Ibrutinib, Gemcitabine, Nab-paclitaxel
- Where
- 86 sites in United States, Belgium and 6 more
- Volunteers
- 430 people
- Sponsor
- Pharmacyclics LLC.
Rheumatoid Arthritis
Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis
CC-292 is an oral agent that is under clinical development for the treatment of rheumatoid arthritis an autoimmune inflammatory disorder.
- Trial name
- NCT01975610
- Testing
- CC-292
- Where
- 27 sites in United States
- Volunteers
- 47 people
- Sponsor
- Celgene
Chronic Lymphocytic Leukemia
Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia (CLL)
- Trial name
- NCT02157324
- Testing
- acalabrutinib, ACP-319
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Acerta Pharma BV
B-Cell Lymphoma, B-Cell Leukemia
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
The purpose of this study is to establish the safety and optimal dose of orally administered PCI-32765 in patients with recurrent B cell lymphoma.
- Trial name
- PCYC-04753 (NCT00849654)
- Testing
- PCI-32765
- Where
- 9 sites in United States
- Volunteers
- 66 people
- Sponsor
- Pharmacyclics LLC.